Business Context and Reporting Period
This Form 8-K was filed by Aadi Bioscience, Inc. (trading symbol: AADI) on January 23, 2023, reporting events occurring on January 17, 2023. The company is a biotechnology firm incorporated in Delaware and listed on The Nasdaq Stock Market LLC. The filing addresses a material definitive agreement regarding the supply of its therapeutic product, Fyarro.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a contractual amendment rather than financial performance results.
Material Changes
On January 17, 2023, Aadi Bioscience, Inc. entered into Amendment No. 1 to its Negotiated Purchase Order Terms and Conditions with Fresenius Kabi, LLC. Key changes include:
- Term Extension: The agreement term was extended until March 31, 2024, subject to further mutual agreement.
- Pricing and Volume: Terms related to pricing and the Company's obligation to purchase minimum quantities of Fyarro were updated and revised.
- Scope: The amendment includes customary terms applicable to the manufacture of therapeutics in the biotechnology industry.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance, management commentary on future outlook, or specific risk factors beyond the context of the supply agreement. The full text of the Amendment is not included in this report and is scheduled to be filed as an exhibit in a subsequent periodic report.
Investor Verification Checklist
- Verify the specific details of the revised pricing and minimum purchase quantity obligations in the subsequent filing containing the full Amendment.
- Confirm the impact of the extended term (through March 31, 2024) on the company's cash flow and inventory management.
- Monitor future periodic reports for the complete text of the agreement with Fresenius Kabi, LLC.